Recro Pharma, Inc. REPH
Day range unavailable
52-week range unavailable
- Market cap
- 123.23M
- Revenue (ttm)
- 75.36M
- Profit margin
- -15.09%
- Shares out
- 56.42M
- Forward P/E
- -11.61
- Analysts
- Strong Buy
- Price target
- 5.00 (+139.2%)
- Earnings date
- May 5, 2022
ALL -5.91 (-73.88%)
Key statistics
- Enterprise value
- 171.67M
- PEG ratio
- -0.61
- Price / sales
- 1.64
- Price / book
- 2.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 125.00%
- Free cash flow
- -468.25K
- Total cash
- 25.22M
- Total debt
- 103.52M
- Return on equity
- -81.32%
- Short % of float
- 1.26%
- 50-day average
- 1.73
- 200-day average
- 1.88
Analyst view
Consensus: strong buy
- Target (low)
- 4.00
- Target (mean)
- 5.00
- Target (high)
- 6.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
May 5, 2022
Expected May 5, 2022. Consensus EPS estimate -0.09.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 5, 2022 | Mar 1, 2022 | -0.04 | — | — | — |
| Mar 1, 2022 | Dec 1, 2021 | -0.07 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -0.05 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Feb 26, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2021 | William Blair | init | — | Outperform |
| May 12, 2020 | Oppenheimer | main | — | Outperform |
| Mar 5, 2020 | Stephens & Co. | main | — | Overweight |
| Nov 26, 2019 | Stephens & Co. | main | — | Overweight |
| Oct 17, 2019 | Stephens & Co. | init | — | Overweight |
| Mar 25, 2019 | Roth Capital | down | Buy | Neutral |
About Recro Pharma, Inc.
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- recrocdmo.com
News
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data 
Earnings Scheduled For November 9, 2021 
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 - 78 Biggest Movers From Friday
Stocks That Hit 52-Week Lows On Thursday - Stocks That Hit 52-Week Lows On Wednesday
- Earnings Scheduled For August 10, 2020
Stocks That Hit 52-Week Lows On Thursday 
Stocks That Hit 52-Week Lows On Wednesday 
Stocks That Hit 52-Week Highs On Friday
Your note
Sign in to keep a note on REPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHTON WILLIAM L | Director | Stock Award(Grant) | Apr 19, 2021 | 80,280 |
| AWM INVESTMENT COMPANY, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 20, 2021 | 0 |
| BERELOWITZ MICHAEL | Director | Stock Award(Grant) | Apr 19, 2021 | 76,546 |
| CHURCHILL WINSTON J. JR. | Director | Stock Award(Grant) | Apr 19, 2021 | 77,982 |
| ENLOE J DAVID JR | Chief Executive Officer | Purchase | Mar 14, 2022 | 524,879 |
| HENWOOD GERALDINE A | Director | Stock Award(Grant) | Apr 19, 2021 | 276,574 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AWM Investment Company, Inc. | 9.01% | 5,081,901 | 8.69M | Dec 30, 2021 |
| Cowen Prime Advisors LLC | 7.45% | 4,204,000 | 7.19M | Dec 30, 2021 |
| Samjo Capital LLC | 5.67% | 3,200,000 | 5.47M | Dec 30, 2021 |
| Athyrium Capital Management, LP | 3.90% | 2,202,420 | 3.77M | Dec 30, 2021 |
| Alyeska Investment Group, L.P. | 3.18% | 1,796,720 | 3.07M | Dec 30, 2021 |
| Vanguard Group, Inc. (The) | 3.00% | 1,694,462 | 2.90M | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.00% | 1,130,309 | 1.93M | Dec 30, 2021 |
| Buffalo Early Stage Growth Fund | 1.22% | 690,000 | 1.18M | Dec 30, 2021 |
| Vanguard Extended Market Index Fund | 0.84% | 472,521 | 808.01K | Dec 30, 2021 |
| First Eagle Small Opportunity Fund | 0.38% | 214,775 | 418.81K | Oct 30, 2021 |
| Fidelity Extended Market Index Fund | 0.38% | 213,994 | 365.93K | Dec 30, 2021 |
| Russell Inv Co-U.S. Small Cap Equity Fund | 0.24% | 136,069 | 265.33K | Oct 30, 2021 |